[{"AccruedLiabilitiesCurrent_0_Q3_USD":16316.0,"OperatingIncomeLoss_2_Q3_USD":-259265.0,"OtherNonoperatingIncome_1_Q3_USD":3042.0,"OtherNonoperatingIncome_2_Q3_USD":3042.0,"OtherPrepaidExpenseCurrent_0_Q3_USD":897311.0,"PaymentsOfStockIssuanceCosts_2_Q3_USD":360267.0,"PaymentsToAcquireRestrictedInvestments_2_Q3_USD":250000000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockValue_0_Q3_USD":null,"ProceedsFromIssuanceInitialPublicOffering_2_Q3_USD":245600000.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q3_USD":6400000.0,"ProceedsFromNotesPayable_2_Q3_USD":300000.0,"ProceedsFromRepaymentsOfRelatedPartyDebt_2_Q3_USD":63787.0,"RepaymentsOfNotesPayable_2_Q3_USD":300000.0,"RepaymentsOfRelatedPartyDebt_2_Q3_USD":25681.0,"RestrictedInvestmentsNoncurrent_0_Q3_USD":250003042.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-6315221.0,"StockholdersEquity_0_Q3_USD":-6314532.0,"StockIssued1_2_Q3_USD":20000.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":250003042.0,"TemporaryEquitySharesOutstanding_0_Q3_shares":25000000.0,"OperatingIncomeLoss_1_Q3_USD":-253940.0,"UnrecognizedTaxBenefits_0_Q3_USD":0.0,"OperatingExpenses_2_Q3_USD":259265.0,"NetIncomeLoss_1_Q3_USD":-250898.0,"AdditionalPaidInCapital_0_Q3_USD":0.0,"AllocatedShareBasedCompensationExpense_0_Q3_USD":0.0,"Assets_0_Q3_USD":251442932.0,"AssetsCurrent_0_Q3_USD":1439890.0,"Cash_0_Q3_USD":542579.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":542579.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_2_Q3_USD":542579.0,"CashEquivalentsAtCarryingValue_0_Q3_USD":0.0,"CashFDICInsuredAmount_0_Q3_USD":250000.0,"CommitmentsAndContingencies_0_Q3_USD":null,"DueFromRelatedParties_0_Q3_USD":30000.0,"DueToRelatedPartiesCurrent_0_Q3_USD":38106.0,"IncreaseDecreaseInAccruedLiabilities_2_Q3_USD":16316.0,"IncreaseDecreaseInPrepaidExpense_2_Q3_USD":897311.0,"InvestmentIncomeInterest_2_Q3_USD":3000.0,"Liabilities_0_Q3_USD":7754422.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":251442932.0,"LiabilitiesCurrent_0_Q3_USD":54422.0,"MarketableSecuritiesNoncurrent_0_Q3_USD":250003042.0,"NetCashProvidedByUsedInFinancingActivities_2_Q3_USD":251677839.0,"NetCashProvidedByUsedInInvestingActivities_2_Q3_USD":-250000000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q3_USD":-1135260.0,"NetIncomeLoss_2_Q3_USD":-256223.0,"OperatingExpenses_1_Q3_USD":253940.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_2_Q3_USD":0.0,"Ticker":"DNAD","CIK":"1850272","name":"SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. IV","OfficialName":"Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"310608600.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211115"}]